Masiuk Tina, Kadakia Parul, Wang Zhenyu
Respiratory Product Development, Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ, USA.
J Pharm Anal. 2016 Oct;6(5):283-291. doi: 10.1016/j.jpha.2016.05.003. Epub 2016 Jun 1.
Current methods for nasal spray formulations have been elementary evaluating the dripping characteristics of a formulation and have not assessed the behavior of the nasal formulation in the presence of varying types of mucus depending on the indication or diseased state. This research investigated the effects of nasal mucus on the dripping behavior of nasal formulations and focused on developing an improved in vitro analytical test method that is more physiologically relevant in characterizing nasal formulation dripping behavior. Method development was performed using simulated nasal mucus preparations for both healthy and diseased states as coatings for the dripping experiment representing a wide range of viscosity. Factors evaluated during development of this in vitro test method included amount of mucus, application of mucus, drying times, and compatibility of the mucus on a C Thin Layer Chromatography (TLC) substrate. The dripping behavior of nasal formulations containing a range of 1% Avicel to 3.5% Avicel was assessed by actuating the nasal spray on a perpendicular TLC plate coated with either healthy or diseased simulated nasal mucus. After actuation of the nasal spray, the dripping of the formulation on the coated TLC plate was measured after the plate was repositioned vertically. The method that was developed generated reproducible results on the dripping behavior of nasal formulations and provided critical information about the compatibility of the formulation with the nasal mucus for different diseased states, aiding in nasal spray formulation development and physical characterization of the nasal spray.
目前用于鼻喷雾剂制剂的方法主要是初步评估制剂的滴流特性,尚未评估在不同类型黏液(取决于适应症或疾病状态)存在下鼻用制剂的行为。本研究调查了鼻黏液对鼻用制剂滴流行为的影响,并着重开发一种改进的体外分析测试方法,该方法在表征鼻用制剂滴流行为方面更具生理学相关性。使用健康和疾病状态下的模拟鼻黏液制剂作为滴流实验的涂层进行方法开发,这些涂层代表了广泛的黏度范围。在开发这种体外测试方法过程中评估的因素包括黏液量、黏液的施加、干燥时间以及黏液在C薄层色谱(TLC)基质上的兼容性。通过在涂有健康或疾病模拟鼻黏液的垂直TLC板上启动鼻喷雾剂,评估含有1%至3.5%微晶纤维素的一系列鼻用制剂的滴流行为。启动鼻喷雾剂后,在将板垂直重新定位后测量制剂在涂覆的TLC板上的滴流情况。所开发的方法在鼻用制剂滴流行为方面产生了可重复的结果,并提供了关于制剂在不同疾病状态下与鼻黏液兼容性的关键信息,有助于鼻喷雾剂制剂的开发和鼻喷雾剂的物理表征。